



US009220698B2

(12) **United States Patent**  
**Ault et al.**

(10) **Patent No.:** **US 9,220,698 B2**  
(45) **Date of Patent:** **\*Dec. 29, 2015**

(54) **METHOD FOR DELIVERING A  
PHARMACEUTICAL COMPOSITION TO  
PATIENT IN NEED THEREOF**

(75) Inventors: **Brian Ault**, Wilmington, DE (US);  
**Mark Sostek**, Wilmington, DE (US);  
**Everardus Orlemans**, Chapel Hill, NC  
(US); **John R. Plachetka**, Chapel Hill,  
NC (US)

(73) Assignees: **Pozen Inc.**, Chapel Hill, NC (US);  
**Horizon Pharma USA, Inc.**, Deerfield,  
IL (US)

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 553 days.

This patent is subject to a terminal dis-  
claimer.

(21) Appl. No.: **12/553,107**

(22) Filed: **Sep. 3, 2009**

(65) **Prior Publication Data**

US 2010/0062064 A1 Mar. 11, 2010

#### **Related U.S. Application Data**

(60) Provisional application No. 61/095,584, filed on Sep.  
9, 2008.

(51) **Int. Cl.**

**A61K 31/4439** (2006.01)

**A61K 31/192** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61K 31/192** (2013.01); **A61K 31/4439**  
(2013.01)

(58) **Field of Classification Search**

CPC ..... **A61K 31/4439**; **A61K 31/192**  
See application file for complete search history.

(56) **References Cited**

#### **U.S. PATENT DOCUMENTS**

4,198,390 A 4/1980 Rider  
4,255,431 A 3/1981 Junggren et al.  
4,344,929 A 8/1982 Bonsen et al.  
4,508,905 A 4/1985 Junggren et al.  
4,554,276 A 11/1985 LaMattina  
4,562,261 A 12/1985 Hirata et al.  
4,619,934 A 10/1986 Sunshine et al.  
4,676,984 A 6/1987 Wu et al.  
4,704,278 A 11/1987 Wu et al.  
4,726,951 A 2/1988 Panoz et al.  
4,738,974 A 4/1988 Brandstrom  
4,757,060 A 7/1988 Lukacsko et al.  
4,758,579 A 7/1988 Kohl et al.  
4,766,117 A 8/1988 Crawford et al.  
4,786,505 A 11/1988 Lovgren et al.  
4,853,230 A 8/1989 Lovgren et al.  
4,865,847 A 9/1989 Gosswein  
4,948,581 A 8/1990 Sawayanagi et al.  
4,965,065 A 10/1990 Lukacsko et al.  
5,026,560 A 6/1991 Makino et al.  
5,035,899 A 7/1991 Saeki et al.

5,037,815 A 8/1991 Lukacsko et al.  
5,043,358 A 8/1991 Lukacsko et al.  
5,051,262 A 9/1991 Panoz et al.  
5,093,132 A 3/1992 Makino et al.  
5,204,118 A 4/1993 Goldman et al.  
5,260,333 A 11/1993 Lukacsko et al.  
5,364,616 A 11/1994 Singer et al.  
5,373,022 A 12/1994 Fawzi et al.  
5,409,709 A 4/1995 Ozawa et al.  
5,417,980 A 5/1995 Goldman et al.  
5,466,436 A 11/1995 Stables  
5,514,663 A 5/1996 Mandel  
5,601,843 A 2/1997 Gimet et al.  
5,631,022 A 5/1997 Mandel et al.  
5,643,960 A 7/1997 Breitner et al.  
5,667,802 A 9/1997 Grimberg  
5,679,376 A 10/1997 Stevens et al.  
5,686,105 A 11/1997 Kelm et al.  
5,702,723 A 12/1997 Griffin  
5,714,504 A 2/1998 Lindberg et al.  
5,716,648 A 2/1998 Halskov et al.  
5,750,531 A 5/1998 Lee et al.  
5,817,338 A 10/1998 Bergstrand et al.  
5,817,340 A 10/1998 Roche et al.  
5,840,737 A 11/1998 Phillips  
5,900,424 A 5/1999 Kallstrom et al.  
5,955,451 A 9/1999 Lichtenberger et al.  
6,013,281 A 1/2000 Lundberg et al.  
6,025,395 A 2/2000 Breitner et al.  
6,093,734 A 7/2000 Garst et al.  
6,132,768 A 10/2000 Sachs et al.  
6,132,771 A 10/2000 Depui et al.  
6,136,344 A 10/2000 Depui et al.  
6,160,020 A 12/2000 Ohannesian et al.  
6,162,816 A 12/2000 Bohlin et al.  
6,183,776 B1 2/2001 Depui et al.  
6,183,779 B1 2/2001 Ouali et al.  
6,207,188 B1 3/2001 Gustavsson et al.

(Continued)

#### **FOREIGN PATENT DOCUMENTS**

AU 2006235929 11/2006  
CA 2139653 7/2000

(Continued)

#### **OTHER PUBLICATIONS**

Abelo et al., "Pharmacodynamic modeling of reversible gastric acid  
pump inhibition in dog and man," European Journal of Pharmaceu-  
tical Sciences, 14, pp. 339-346 (2001).

(Continued)

*Primary Examiner* — Gina Justice

(74) *Attorney, Agent, or Firm* — Parker Highlander PLLC

(57) **ABSTRACT**

The present disclosure is directed to a method for delivering  
a pharmaceutical composition to a patient in need thereof,  
comprising: administering to said patient a pharmaceutical  
composition in unit dose form comprising naproxen, or phar-  
maceutically acceptable salt thereof, and esomeprazole, or  
pharmaceutically acceptable salt thereof.

**7 Claims, 9 Drawing Sheets**